The cost-effectiveness of biopharmaceuticals

References

• Gosse M, Manocchia M. The First Biopharmaceuticals Approved in the United States: 1980–2004. Drug Inf J 1996; 30:991 - 1001; http://dx.doi.org/10.1177/009286159603000416
   Google Scholar
• Reichert JM. Trends in US approvals: new biopharmaceuticals and vaccines. Trends Biotechnol 2006; 24:293 - 298; http://dx.doi.org/10.1016/j.tibtech.2006.05.003; PMID: 16759723
   PubMed Web of Science ®Google Scholar
• Trusheim M, Aitkin M, Berndt E. Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?. Forum for Health Economics & Policy 2010; 13:4
   Google Scholar
• Top 200 Prescription Medicines by Sales 2009. MedAdNews 2010; 29:9 - 15
   Google Scholar
• IMS Institute of Health Care Informatics. The Use of Medicines in the United States: Review of 2010 November 15, 2011 See: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf
   Google Scholar
• Blackstone E, Fuhr J. Biopharmaceuticals: The Economic Equation. Biotechnology Healthcare 2007; 41 - 45
   PubMedGoogle Scholar
• Simon F. Market access for biopharmaceuticals: new challenges. Health Aff (Millwood) 2006; 25:1363 - 1370; http://dx.doi.org/10.1377/hlthaff.25.5.1363; PMID: 16966734
   PubMed Web of Science ®Google Scholar
• Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia and Canada. JAMA 2009; 302:1437 - 1443; http://dx.doi.org/10.1001/jama.2009.1409; PMID: 19809025
   PubMed Web of Science ®Google Scholar
• Sorenson C, Drummond M, Panos K. Ensuring Value for Money: The Role of Health Technology Assessment in the European Union. European Observatory on Health Systems and Policies November 15, 2011 See http://www.euro.who.int/__data/assets/pdf_file/0011/98291/E91271.pdf
   Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein M. Cost-Effectiveness in Health and Medicine 1996; New York, NY Oxford University Press
   Google Scholar
• Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature 1976–2001. Value Health 2005; 8:3 - 9; http://dx.doi.org/10.1111/j.1524-4733.2005.04010.x; PMID: 15841889
   PubMed Web of Science ®Google Scholar
• Drummond MF, O'Brien B, Stoddart GL, Torrance G. Methods for the Evaluation of Health Care Programs 1997; Oxford Oxford University Press 2
   Google Scholar
• Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA 1996; 276:1172 - 1177; Panel on Cost-Effectiveness in Health and Medicine http://dx.doi.org/10.1001/jama.1996.03540140060028; PMID: 8827972
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics 2009; 27:861 - 872; http://dx.doi.org/10.2165/11312720-000000000-00000; PMID: 19803540
   PubMed Web of Science ®Google Scholar
• Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000; 68:144 - 149; http://dx.doi.org/10.1136/jnnp.68.2.144; PMID: 10644777
   PubMed Web of Science ®Google Scholar
• Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002; 113:400 - 408; http://dx.doi.org/10.1016/S0002-9343(02)01243-3; PMID: 12401535
   PubMed Web of Science ®Google Scholar
• Martin SC, Gagnon DD, Zhang L, Bokemeyer C, Van Marwijk Kooy M, van Hout B. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. Pharmacoeconomics 2003; 21:1153 - 1169; http://dx.doi.org/10.2165/00019053-200321160-00002; PMID: 14594437
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008; 115:1039 - 1045
   PubMed Web of Science ®Google Scholar
• Tappenden P, Jones R, Paisley S, Carroll C. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007; 43:2487 - 2494; http://dx.doi.org/10.1016/j.ejca.2007.08.017; PMID: 17910914
   PubMed Web of Science ®Google Scholar
• Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007; 62:149 - 153; http://dx.doi.org/10.1111/j.1398-9995.2006.01310.x; PMID: 17298423
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford) 2008; 47:535 - 541; http://dx.doi.org/10.1093/rheumatology/ken007; PMID: 18356179
   PubMed Web of Science ®Google Scholar
• Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276:1339 - 1341; Panel on Cost-Effectiveness in Health and Medicine http://dx.doi.org/10.1001/jama.276.16.1339; PMID: 8861994
   PubMed Web of Science ®Google Scholar
• Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010; 102:82 - 88; http://dx.doi.org/10.1093/jnci/djp472; PMID: 20056956
   PubMed Web of Science ®Google Scholar
• The Center for the Evaluation of Value and Risk in Health. Publications Using Registry Data November 15, 2011 See https://research.tufts-nemc.org/cear4/Resources/Publications.aspx
   Google Scholar
• Rader RA. (Re)defining biopharmaceutical. Nat Biotechnol 2008; 26:743 - 751; http://dx.doi.org/10.1038/nbt0708-743; PMID: 18612293
   PubMed Web of Science ®Google Scholar
• Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006; 332:699 - 703; http://dx.doi.org/10.1136/bmj.38737.607558.80; PMID: 16495332
   PubMed Web of Science ®Google Scholar
• Health Data OECD. 2010—Frequently Requested Data November 15, 2011 See http://www.oecd.org/document/16/0,3343,en_2649_34631_2085200_1_1_1_1,00.html
   Google Scholar
• Takeda A, Jones J, Shepherd J, Davidson P, Price A. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. J Viral Hepat 2007; 14:75 - 88; http://dx.doi.org/10.1111/j.1365-2893.2006.00808.x; PMID: 17244247
   PubMed Web of Science ®Google Scholar
• Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, et al, Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 2009; 101:1182 - 1192; http://dx.doi.org/10.1093/jnci/djp232; PMID: 19666851
   PubMed Web of Science ®Google Scholar
• Johnson A. Cost-Effectiveness of Cancer Drugs is Questioned. The Wall Street Journal 2009;
   Google Scholar
• Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101:1044 - 1048; http://dx.doi.org/10.1093/jnci/djp177; PMID: 19564563
   PubMed Web of Science ®Google Scholar
• Scott DL, Kingsley G. Clinical effectiveness of biologics in clinical practice. Arthritis Res Ther 2010; 12:115; http://dx.doi.org/10.1186/ar2970; PMID: 20447320
   PubMed Web of Science ®Google Scholar
• Kavanaugh A. Pharmacoeconomic considerations in the treatment of psoriatic arthritis. Rheumatology (Oxford) 2006; 45:790 - 791; http://dx.doi.org/10.1093/rheumatology/kel153; PMID: 16705044
   PubMed Web of Science ®Google Scholar
• Wilson A, Cohen J. Patient access to new cancer drugs in the United States and Australia. Value Health 2011; 14:944 - 952; http://dx.doi.org/10.1016/j.jval.2011.05.004; PMID: 21914517
   PubMed Web of Science ®Google Scholar
• Raferty JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust 2008; 188:26 - 28
   PubMed Web of Science ®Google Scholar
• Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res 2011; 3:29 - 36; http://dx.doi.org/10.2147/CEOR.S12494; PMID: 21935330
   PubMedGoogle Scholar
• Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med 2011; 365:385 - 388; http://dx.doi.org/10.1056/NEJMp1107285; PMID: 21812668
   PubMed Web of Science ®Google Scholar